| First author             | Published time | Study design       | Study location   | Study population                                      | Vaccine type | No. people vaccinated | No. people with adverse reactions | No. people with severe adverse reactions | No. people with vaccine-related death | risk of bias |
|-------------------------|----------------|--------------------|------------------|-------------------------------------------------------|--------------|-----------------------|-----------------------------------|------------------------------------------|---------------------------------------|--------------|
| China CDC               | 2021.5         | cross-sectional    | China            | general population                                     | Any          | 265000000             | 31434                            | 5544                                      | ..                                     | moderate     |
| David K. Shay           | 2021.5         | cross-sectional    | USA              | general population                                     | Ad26.COV2.S  | 79800000             | 13725                            | 343                                       | 88                                    | moderate     |
| Laith J. Abu-Raddad     | 2021.6         | cross-sectional    | Saudi Arabia     | general population                                     | BNT162b2     | 130                  | 52                               | ..                                        | ..                                    | moderate     |
| S Andrzejczak-Grządko   | 2021.7         | cross-sectional    | Poland           | general population                                     | AZD1222      | 385                  | 255                              | ..                                        | ..                                    | moderate     |
| Aurelie Baldolli        | 2021.7         | cross-sectional    | France           | general population                                     | BNT162b2     | 1987                 | 1136                             | 183                                       | ..                                     | moderate     |
|                        |                |                    |                  | patients with a medical history of COVID-19 disease    | BNT162b2     | 61                   | 45                               | 9                                         | ..                                    | moderate     |
| Somy Cherian            | 2021.6         | cross-sectional    | India            | patients with rheumatic diseases                       | Any          | 724                  | 436                              | ..                                        | ..                                    | moderate     |
| Patrice Chevallier      | 2021.6         | cohort study       | France           | allogeneic hematopoietic stem-cell recipients          | BNT162b2     | 94                   | 45                               | ..                                        | ..                                    | moderate     |
| Caoolfhionn M Connolly  | 2021.3         | cohort study       | USA              | patients with rheumatic diseases                       | Any          | 325                  | ..                               | 1                                         | ..                                    | moderate     |
| Victoria Furer          | 2021.6         | cohort study       | Israel           | adult patients with autoimmune inflammatory rheumatic diseases | BNT162b2     | 670                  | ..                               | 2                                         | 2                                     | moderate     |
| Julianne Gee            | 2021.2         | cross-sectional    |                  |                                                        | Any          | 13794904             | 6994                             | 753                                       | 113                                   | moderate     |
| Takanao Hashimoto       | 2021.6         | cross-sectional    | Japan            | Health Care Workers                                    | BNT162b2     | 181184               | ..                               | 37                                        | ..                                    | moderate     |
| Gang Lv                 | 2021.5         | cross-sectional    | USA              | general population                                     | Any          | 6688231              | ..                               | 55                                        | 55                                    | moderate     |
|                        |                |                    |                  | long-term care facilities                              | Any          | 693246               | ..                               | 37                                        | 37                                    |              |
| Pagotto, V.             | 2021.6         | cross-sectional    | Argentina        | healthcare workers                                     | Sputnik V COVID-19 vaccine | 683   | 487 | 12 | .. | low |
| C. Signorelli           | 2021.6         | cross-sectional    | Italy            | general population                                     | BNT162b2     | 37900               | 142                              | ..                                        | ..                                    | moderate     |
| Author          | Year  | Study Type  | Country                        | Target Group                                           | Vaccine(s)                              | Mean Age | Median Age | Range Age | Status   |
|-----------------|-------|-------------|--------------------------------|-------------------------------------------------------|-----------------------------------------|----------|------------|-----------|----------|
| Riad, A.        | 2021.6| cross-sectional study | Turkey                        | Healthcare workers                                     | CoronaVac                              | 780      | 487        |          | low      |
| Quiroga, B.     | 2021.7| cross-sectional study | Spanish                        | Nephrologists                                          | BNT162b2, mRNA-1273                    | 565      | 422        |          | low      |
| Vallée, A.      | 2021.7| cross-sectional study | France                         | Healthcare workers                                     | AZD1222                                | 451      | 274        |          | moderate |
| McMurry, R.     | 2021.7| cohort study    | USA                            |                                                       | BNT162b2                               | 51795    | 11         |          | low      |
| Wang, J.        | 2021.4| cohort study    | China                          | Patients with non-alcoholic fatty liver disease        | Beijing Institute of Biological Products Co., Ltd. | 381      | 112        |          | moderate |
| Monin, L.       | 2021.5| cohort study    | London                         | Patients with cancer                                    | BNT162b2                               | 140      | 64         |          | low      |
| Ram, R.         | 2021.7| cohort study    | Israeli                        | Patients who underwent either allogeneic HCT or CD19-based chimeric antigen receptor T cell (CART) therapy | BNT162b2                               | 80       | 11         |          | moderate |
| Zhang, M. X.    | 2021.5| Cross-Sectional Study | China                          | Healthcare workers                                     | CoronaVac                              | 76       | 18         |          | moderate |
| Rosman, Y.      | 2021.7| cross-sectional study | USA                            | Patients with mast cell disorders                      | BNT162b2                               | 1397     | 204        |          | moderate |
| Riad, A.        | 2021.6| Cross-Sectional Study | Germany and Czech Republic     | Healthcare Workers                                      | AZD1222                                | 92       | 87         |          | moderate |
| Revon-Riviere, G.| 2021.7| cross-sectional study | France                         | Adolescents and young adults with cancer               | BNT162b2                               | 13       | 8          |          | low      |
| Peled, Y.       | 2021.5| cohort study    | Israel                         | Heart transplant recipients                             | BNT162b2                               | 77       | 46         |          | low      |